XTX Topco Ltd Buys New Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

XTX Topco Ltd bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,891 shares of the company's stock, valued at approximately $674,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after buying an additional 273 shares during the last quarter. Innealta Capital LLC purchased a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after purchasing an additional 398 shares during the period. Blue Trust Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. purchased a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth $78,000. Hedge funds and other institutional investors own 65.09% of the company's stock.

Insider Activity

In related news, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 7.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares in the company, valued at approximately $3,900,522.90. This trade represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,533 shares of company stock worth $1,676,542 over the last quarter. Insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Stock Down 5.1 %

AMPH traded down $2.26 during trading on Friday, hitting $42.24. 772,411 shares of the company's stock were exchanged, compared to its average volume of 401,530. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The business's 50 day moving average is $47.22 and its two-hundred day moving average is $44.62. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The stock has a market cap of $2.03 billion, a P/E ratio of 14.83, a PEG ratio of 0.87 and a beta of 0.78.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on AMPH shares. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $60.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.